GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CBD Life Sciences Inc (OTCPK:CBDL) » Definitions » Debt-to-EBITDA

CBD Life Sciences (CBD Life Sciences) Debt-to-EBITDA : 0.00 (As of Sep. 2015)


View and export this data going back to 2009. Start your Free Trial

What is CBD Life Sciences Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

CBD Life Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2015 was $0.00 Mil. CBD Life Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2015 was $0.00 Mil. CBD Life Sciences's annualized EBITDA for the quarter that ended in Sep. 2015 was $-0.07 Mil. CBD Life Sciences's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2015 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for CBD Life Sciences's Debt-to-EBITDA or its related term are showing as below:

CBDL's Debt-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.69
* Ranked among companies with meaningful Debt-to-EBITDA only.

CBD Life Sciences Debt-to-EBITDA Historical Data

The historical data trend for CBD Life Sciences's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CBD Life Sciences Debt-to-EBITDA Chart

CBD Life Sciences Annual Data
Trend Dec11 Dec12 Dec13 Dec14
Debt-to-EBITDA
- - - -

CBD Life Sciences Quarterly Data
Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of CBD Life Sciences's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, CBD Life Sciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CBD Life Sciences's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CBD Life Sciences's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where CBD Life Sciences's Debt-to-EBITDA falls into.



CBD Life Sciences Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

CBD Life Sciences's Debt-to-EBITDA for the fiscal year that ended in Dec. 2014 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -0.742
=0.00

CBD Life Sciences's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2015 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -0.072
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2015) EBITDA data.


CBD Life Sciences  (OTCPK:CBDL) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


CBD Life Sciences Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of CBD Life Sciences's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


CBD Life Sciences (CBD Life Sciences) Business Description

Traded in Other Exchanges
N/A
Address
10853 N. Frank Llyod Wright Boulevard, Suite 108, Scottsdale, AZ, USA, 85259
CBD Life Sciences Inc is developing and marketing a line of cannabidiol based organic products such as hemp drops, massage oils, recovery pain relief creams, anxiety and sleep solutions supplements, edibles, and a full line of pet products. The company is also in the process of developing an anti-aging skin product line.